Darlene Males, APRN
Family · Wakefield, RINPI 1821599101
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $903 and has fallen 79.6% since, to $184 in 2025.
Across 146 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$629
- Pfizer$453
- GSK$439
- Amgen$323
- AbbVie$154
- Nestle Healthcare Nutrition Inc.$117
- plus $696 from 17 others
What the payments were for
- Food & beverage$2,812100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 31 | $629 |
| Pfizer | 27 | $453 |
| GSK | 25 | $439 |
| Amgen | 15 | $323 |
| AbbVie | 6 | $154 |
| Nestle Healthcare Nutrition Inc. | 6 | $117 |
| Boehringer Ingelheim | 4 | $97 |
| Esperion Therapeutics, Inc. | 5 | $89 |
| Novo Nordisk | 4 | $88 |
| Exact Sciences | 5 | $76 |
| Merck | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Lilly USA, LLC | 2 | $52 |
| Verona Pharma, Inc. | 1 | $30 |
| Biogen | 1 | $24 |
| Genentech USA, Inc. | 2 | $23 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novartis | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
How this compares
$2,812 in reported general payments places this provider in the 85th percentile of 457 family providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort | 20 | $1,593 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 109 | $1,143 |
| Mesalamine | 12 | $836 |
| Azithromycin | 100 | $820 |
| CefuroximeCefuroxime Axetil | 37 | $632 |
| Gabapentin | 33 | $496 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $396 |
| Amlodipine Besylate | 33 | $352 |
| Omeprazole | 12 | $337 |
| Sertraline Hcl | 22 | $325 |
| Methylprednisolone | 34 | $319 |
| Allopurinol | 19 | $288 |
| Lisinopril | 36 | $283 |
| Cefdinir | 12 | $260 |
| Clindamycin Hcl | 21 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $453 | $017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 457 family providers in Rhode Island.
Other family in Wakefield
- Carol RobinsonWarwick$82K
- Mark ClarkeSmithfield$37K
- Olga FedorenkoCoventry$24K
- Alicia VatterWarwick$15K
- Kaleigh RapozaJohnston$14K
- David RamosRiverside$14K
- Sharon BensonNorth Smithfield$12K
- Michelle Blade MelloWest Warwick$12K
- Shrenik VyasLincoln$11K
- Hollie ColucciWest Warwick$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.